Stock News

MRI-measured muscle fat fraction replaces dynamometry in the 53-boy Duchenne study, with placebo-controlled data expected in Q1 2027.

Free cash outflow narrowed to C$15.5 million as international sales grew, while charges on Canopy USA assets weighed on earnings.

Quarterly losses narrowed, but operating income fell and September-end financial statements show US$41.2 million in cash plus restricted funds.

The proposed common stamp would reduce the number of stamp types from 13 to six, with a Jan. 1, 2028 start date and no company savings estimate.

Former Silver47 holders own about 43 per cent of the combined company, which targets commercial production at its Idaho mine by year-end.

International COVID-vaccine sales and lower research spending lift earnings, while convertible financing boosts cash and investments.

The cloud operator says US$6 billion of planned funding remains a target, while contracted run-rate revenue awaits commissioning.

The award adds a technology-development phase, but AST discloses no contract value, funded amount or delivery schedule.

Promontorio Sur returned 12.20 metres at 238 grams per tonne silver equivalent, with an updated resource targeted for the fourth quarter.

The New Zealand proposal seeks mine and infrastructure approvals, with a feasibility study targeted for the fourth quarter of 2026.

Quarter-end cash, restricted cash and deposits totalled US$840.6 million before the October CanAdelaar acquisition.

Armenia's conditional authorizations cover previously treated metastatic colorectal cancer; existing financing supports operations into 2027.

Assays confirm mineralization 500 metres beyond the deposit and higher grades inside Hurricane's southern resource shell.

The proposed share deal would give Aya about 19.11 per cent of Sama and add Moroccan tungsten, copper and molybdenum exposure.

The 353-patient VOCAL study tested three-times-weekly vadadustat, a regimen that remains investigational despite Vafseo's daily-use approval.

Quarterly capital spending reached US$985.1 million, while the company targets early 2027 completion of its first colocation buildout.

Recorlev revenue grew 93 per cent as Xeris lifted its annual forecast and kept a pivotal thyroid study on track for year-end.

Medical-only quarterly results limit year-over-year comparisons as Trulieve reports a US$65 million mortgage repayment after September.

Two U.S. utilities will take annual deliveries through 2032 at prevailing spot prices, with no pricing floors, ceilings or discounts.

Shipments from Brazil to La Rochelle are expected in 2028 under an initial term through 2034, while pricing and annual tonnage remain undisclosed.

Management estimates up to US$2.5 million in additional survey work over two years, subject to successful delivery and further awards.

The neuroscience developer expects epilepsy safety data this quarter and FDA talks on its bipolar mania program in early 2027.

The company says current assets exceeded current liabilities in October, while Australian admission still requires ASX review and approval.

Third-quarter revenue reached US$393.1 million, while the medical-device maker kept its annual adjusted free-cash-flow target unchanged.

Eagle Nuclear would issue 0.0167 shares for each Noble Plains share, with a definitive agreement still to be negotiated.

Cash and investments fell US$41.9 million over the quarter as the gene therapy developer prepared for a potential AMT-130 launch.

Participation notices and a subscription agreement would preserve three investors' stakes, with closing expected Nov. 6.

Cash reached US$48.2 million as licensing supported operations, while approaching hemp restrictions threaten current products.

The Anais dyke interval includes 142 metres at 1.97 per cent lithium oxide, with true thickness estimated at about 80 per cent of drilled length.

The company identifies its entire Florida retail network, while federal security, inventory and recordkeeping requirements continue.

A$500,000 leaves escrow as the AIM company retains contingent copper interests and directs proceeds towards Redmoor tungsten development.

The Madsen-Rowan plan calls for C$200 million in growth capital and forecasts higher production once Rowan starts in 2029.

An existing customer expands data volume by 150 per cent, but delivery timing and the exact contract value remain undisclosed.

Collection succeeded in 94.7 per cent of patients, but the retrospective analysis measures feasibility rather than comparative cancer outcomes.

North American production incentives contributed 416.9 billion won as storage shipments grew and European plant utilization improved.

The non-brokered offering would add up to 8 million shares and 4 million warrants, with proceeds for exploration and working capital.

The gold-bearing intersection is measured along drill core, while true vein widths and economic antimony recovery remain undetermined.

Quarter-end liquidity excludes a US$250 million loan draw and a US$70 million payment due under its amended licensing deal.

The completed 36,239-metre infill program targets early mining areas, with East Pit assays still expected in the coming months.

Officially reported purchases totalled 120 tonnes, leaving most of the World Gold Council’s quarterly estimate outside disclosed reserve data.